Discovery Life Sciences™ Further Validates Quality of its Biospecimen Solutions by Participating in VERIF.i ® , Scientist.com’s Supplier Pre-assessment Program
Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i®, the company’s supplier pre-assessment program, has been used by Discovery Life Sciences to successfully complete an on-site assessment of its collection of 10 million research-quality biospecimens. VERIF.i was developed to help Scientist.com marketplace suppliers demonstrate the superior quality of their research offerings and their adherence to best practices. It also helps offset supplier and client costs associated with repetitive due diligence audit requests.
“Discovery has one of the world’s largest collections of high quality, ethically procured and characterized biospecimens from normal and diseased donors integrated with state-of-the-art CLIA-certified, CAP-accredited multi-omic service laboratories,” stated Jay Scherer, COO at Discovery Life Sciences. “We participated in Scientist.com’s VERIF.i program to demonstrate our strong and continued commitment to offering high quality and ethical biospecimen solutions.”
Constructed as an expansion of Scientist.com’s award-winning COMPLi® solution, VERIF.i gives suppliers of regulated research services, such as human biospecimen acquisition, the opportunity to proactively communicate their quality standards against pre-defined criteria developed for use across the biopharma industry. VERIF.i assessments are carried out by independent, third-party auditors during an on-site inspection. The pre-assessments help suppliers demonstrate their quality and capabilities, while also helping researchers on and off the marketplace acquire human biological samples with more confidence, with lower risk and in less time.
“Human biospecimens are used across the entire drug discovery research pipeline and have become an invaluable resource for the development of new precision medicines,” stated Matt McLoughlin, SVP of Categories & Compliance at Scientist.com. “VERIF.i creates a standardized process that helps researchers and suppliers reduce the high costs and resources required to ensure visibility, traceability and transparency of these solutions without sacrificing quality or ethics; it also provides confidence to donors that their samples are being used to help others and are treated in accordance with their wishes.”
For more information visit https://www.scientist.com/verifi/
About Discovery Life Sciences
Discovery Life Sciences is the company of Biospecimen and Biomarker Specialists™, combining the world’s largest commercial biospecimen inventory and procurement network with preeminent multi-omic biomarker service laboratories to accelerate new therapies supported by biomarker and companion diagnostic programs for cancer, infectious disease, and other rare and complex conditions. We are a leading provider of highly characterized human cellular starting materials and expert multi-omic analytical services to advance cell and gene therapy research, development, and manufacturing programs.
HudsonAlpha Discovery® is Discovery’s sequencing and bioinformatics division ─ a globally recognized service laboratory that leverages the most current genomic research technologies to support discovery, translational, and clinical research comprehensively.
Driven by leading scientific expertise and innovative use of current technologies, the Discovery team engages and consults with customers to overcome obstacles more rapidly and obtain results to make critical research and development decisions at market-leading speed. We are Science at your Service™! For more information, visit dls.com.
Scientist.com’s mission is to empower and connect scientists worldwide. By transforming the way scientific research is performed, our Science as a Service® platform accelerates discoveries that prevent and cure disease, address climate change and help secure global food and energy supplies. We combine sophisticated AI technology with white-glove Research Concierge® support to enable scientists to run more innovative experiments in less time and at lower cost.
Visit scientist.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+1 858 771-3813 ext. 187
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release
Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet
Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release
On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan
Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release
Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of
Trading Central wins at the Technical Analyst Awards26.5.2022 17:30:00 CEST | Press release
The Technical Analyst Awards recognize the best in market research, financial data, software and artificial intelligence. At the 2022 edition, industry peers voted Trading Central a winner in three categories: Best AI Product, Most Innovative New Product & Best Multi-Asset Data Provider. Trading Central’s suite of embeddable apps & APIs power the world’s leading online broker platforms to support investors and active traders throughout their decision making journey. We’re proud to be recognized for our relentless efforts to challenge ourselves, innovate and disrupt the industry. TC Market Buzz® for Best AI Product Read less, know more TC Market Buzz leverages Artificial Intelligence to make sense of the millions of news headlines, social media posts and articles posted online every day. It replaces static headlines with simple, compelling and informative data visualizations. Users can: Identify what instruments are buzzing based on news volume View the most discussed topics for an inst
SoftServe Expands Partnership with Google Cloud for Launch of New Manufacturing Solutions26.5.2022 15:05:00 CEST | Press release
SoftServe, a leading digital authority and consulting company, has been unveiled as a services partner of two new Google Cloud manufacturing solutions. The solutions—Manufacturing Data Engine and Manufacturing Connect—were announced earlier this month at the virtual Google Cloud Manufacturing Spotlight Event and are positioned to accelerate and scale digital transformation projects in the manufacturing sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220526005027/en/ SoftServe Expands Partnership with Google Cloud for Launch of New Manufacturing Solutions (Graphic: Business Wire) In partnership with Google Cloud, SoftServe provided valuable feedback in the development of the solutions, from early-stage implementation to launch. Manufacturing Data Engineis an end-to-end solution that processes, contextualizes, and stores factory data on Google Cloud’s market-leading data platform, providing a blueprint for the data.Manu